Visible Patient S.A.S.

Visible Patient S. A. S. is a pioneering online laboratory specializing in 3D modeling of medical images, aimed at enhancing the visualization and interpretation of complex medical data for healthcare professionals and patients alike.

Founded in 2013 in Strasbourg, France, Visible Patient S. A. S. focuses on transforming traditional 2D medical imaging into interactive 3D models for improved surgical planning and patient education.

The company has successfully closed 5 deals since inception, with its latest funding round in January 2021, securing EUR 6. 548 mn from investors including Capital Grand Est, Credit Mutuel Equity, and Johnson & Johnson Innovation, bringing the total amount raised to EUR 6. 480 mn and establishing a current valuation of EUR 29. 761 mn.

Visible Patient operates as the first online laboratory dedicated to the 3D modeling of medical images, providing healthcare professionals and patients with innovative solutions for better visualization and understanding of complex medical data. The core product offering focuses on transforming traditional 2D medical images such as CT scans and MRIs into interactive 3D models, which can be utilized for preoperative planning, patient education, and enhanced surgical precision. This service is designed to address critical challenges in the healthcare sector, enabling medical teams to visualize anatomical structures in detail, ultimately improving patient outcomes. The primary customer base includes hospitals, surgical centers, and medical practitioners across North America and Europe, where advanced healthcare solutions are increasingly in demand.

In the most recent year, 2016, Visible Patient generated revenue of EUR 105,663. 20, while recording an EBITDA of EUR -1,075,763. 80. Revenue is primarily derived from a subscription model catering to healthcare institutions and professionals leveraging their 3D modeling services, ensuring integration of advanced imaging technology into clinical workflows.

Visible Patient plans to utilize the capital raised in January 2021 to expand its product offerings and enhance its technological capabilities. Upcoming initiatives include the launch of new features for their 3D modeling platform aimed at further aiding surgical precision and patient education. The company is also targeting expansion into additional markets across Europe and North America to meet growing demand, with plans to initiate these efforts by the end of 2023.